Longboard Pharmaceuticals
Latest round
- Series A
Last raised
- Oct 2020
Total raised
- $56M
Investors
- 5
About Longboard Pharmaceuticals
Longboard Pharmaceuticals, Inc.Founded in 2020 and headquartered in San Diego, US, Longboard Pharmaceuticals specializes in creating treatments for neurological conditions.Longboard Pharmaceuticals focuses on developing innovative therapies aimed at treating neurological and rare diseases. The company's main product offerings center around a pipeline of GPCR-targeted medicines, which leverage over 20 years of research in G protein-coupled receptors (GPCRs). These therapies address various aspects of human physiology and are designed to be potentially best-in-class solutions for patients. Longboard's client base includes healthcare providers, research institutions, and pharmaceutical partners, with an emphasis on both clinical and commercial applications.Longboard Pharmaceuticals generates revenue primarily through partnerships and collaborations with pharmaceutical companies and research institutions. The transaction structure typically involves agreements for licensing and co-development of its GPCR-targeted drug candidates, which may include milestone payments and royalties based on future sales. While specific pricing details for the therapies are not disclosed, the company’s flagship products are expected to be positioned competitively within the market. Revenue streams are anticipated to arise from both direct-to-consumer and B2B channels, as the company aims to establish its presence in the neurology sector through strategic collaborations and partnerships that facilitate access to its therapies.5 billion from Lundbeck to enhance its capabilities and accelerate growth. The company aims to expand its product pipeline with new GPCR-targeted therapies, although specific release dates have not been disclosed. Additionally, Longboard is targeting expansion into European and Asian markets, expected to be completed by 2025, to meet the rising demand for its innovative neurological treatments.
Who invested in Longboard Pharmaceuticals
5 investors across 1 round
See all investors in Longboard Pharmaceuticals
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Oct 27, 2020
Amount
$56M
Investors
Questions about Longboard Pharmaceuticals
Who invested in Longboard Pharmaceuticals?
Longboard Pharmaceuticals has 5 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Longboard Pharmaceuticals raised?
Longboard Pharmaceuticals has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Longboard Pharmaceuticals last raise money?
Longboard Pharmaceuticals's most recent round on record is a Series A, in Oct 2020.
What does Longboard Pharmaceuticals do?
Longboard Pharmaceuticals, Inc.
Where is Longboard Pharmaceuticals headquartered?
Longboard Pharmaceuticals is headquartered in San Diego, US.
Which VCs invest in companies like Longboard Pharmaceuticals?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Longboard Pharmaceuticals's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like Longboard Pharmaceuticals? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.